Key facts
- CardiaTec’s last known valuation is $16.0M (Oct 2024).
- It has raised $8.5M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Plug and Play Tech Center, Ascension, Cambridge Enterprise Ventures, APEX Ventures, Elevation Capital (Canada) — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for CardiaTec
- ·The full record, as it builds
Funding rounds
No funding rounds for CardiaTec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CardiaTec
Operator of an artificial intelligence (AI) drug target discovery company intended to transform the biology behind cardiovascular disease. The company develops a target identification and novel drug discovery platform to deliver therapeutics for cardiovascular diseases, enabling healthcare professionals to address the unmet needs surrounding CAD diagnostics, patient stratification, and therapeutics.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2021
- Employees
- 17
- Website
- cardiatec.ai/
- Ownership
- Privately Held (backing)
CardiaTec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CardiaTec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CardiaTec in its N-PORT filings yet. We sweep new filings monthly.